dc.creator | BORGES, Anna Paula de Sa | |
dc.creator | GUIDONI, Camilo Molino | |
dc.creator | FERREIRA, Ligia Domingues | |
dc.creator | FREITAS, Osvaldo de | |
dc.creator | PEREIRA, Leonardo Regis Leira | |
dc.date.accessioned | 2012-10-19T03:42:01Z | |
dc.date.accessioned | 2018-07-04T14:58:01Z | |
dc.date.available | 2012-10-19T03:42:01Z | |
dc.date.available | 2018-07-04T14:58:01Z | |
dc.date.created | 2012-10-19T03:42:01Z | |
dc.date.issued | 2010 | |
dc.identifier | PHARMACY WORLD & SCIENCE, v.32, n.6, p.730-736, 2010 | |
dc.identifier | 0928-1231 | |
dc.identifier | http://producao.usp.br/handle/BDPI/20135 | |
dc.identifier | 10.1007/s11096-010-9428-3 | |
dc.identifier | http://dx.doi.org/10.1007/s11096-010-9428-3 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1616919 | |
dc.description.abstract | Objective To evaluate the efficiency of pharmaceutical care on the control of clinical parameters, such as fasting glycaemia and glycosylated haemoglobin in patients with Type 2 Diabetes mellitus. Setting This study was conducted at the Training and Community Health Centre of the College of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. Methods A prospective and experimental study was conducted with 71 participants divided in two groups: (i) pharmaceutical care group (n=40), and (ii) the control group (n=31). The distribution of patients within these groups was made casually, and the patients were monitored for 12 months. Main outcome measure: Values for fasting glycaemia and glycosylated haemoglobin were collected. Results Mean values of fasting glycaemia in the pharmaceutical care group were significantly reduced whilst a small reduction was detected in the control group at the same time. A significant reduction in the levels of glycosylated haemoglobin was detected in patients in the pharmaceutical care group, and an average increase was observed in the control group. Furthermore, the follow-up of the intervention group by a pharmacist contributed to the resolution of 62.7% of 142 drug therapy problems identified. Conclusion In Brazil, the information provided by a pharmacist to patients with Type 2 Diabetes mellitus increases compliance to treatment, solving or reducing the Drug Therapy Problem and, consequently, improving glycaemic control. | |
dc.language | eng | |
dc.publisher | SPRINGER | |
dc.relation | Pharmacy World & Science | |
dc.rights | Copyright SPRINGER | |
dc.rights | restrictedAccess | |
dc.subject | Brazil | |
dc.subject | Brazilian Public Health System | |
dc.subject | Compliance | |
dc.subject | Fasting glycaemia | |
dc.subject | Glycosylated haemoglobin | |
dc.subject | Pharmacist | |
dc.subject | Pharmaceutical Care | |
dc.subject | Type 2 Diabetes mellitus | |
dc.title | The Pharmaceutical care of patients with type 2 diabetes mellitus | |
dc.type | Artículos de revistas | |